Depomed (DEPO) Misses Q3 EPS by 7c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/21/2026
- Wall St set for higher open as AI stocks rise, oil slides
- Oil prices slide to 11-day low on hopes of US-Iran diplomacy, Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
- Far-left party wins Berlin election, pledging to nationalise housing
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- Qatar Investment Authority targets $20B partnership with JPMorgan - Bloomberg
- Wall St set for higher open as AI stocks rise, oil slides
- Streamflation drives 39% of Americans to cancel streaming in 6 months
Leerink Keeps Depomed (DEPO) at 'Outperform'; Disappointing Q3 Steps-up Pressure to Sell
November 8, 2016 11:00 AM ESTLeerink affirms its Outperform rating and $22 price target on Depomed (Nasdaq: DEPO) following Q3 results and update on Monday night.
Analyst Jason M. Gerberry commented today, DEPO reported disappointing 3Q results, missing our/Streets revenue forecasts by 13% and reducing 2016 revenue guidance for the third consecutive qtr. The miss... More
Cantor Fitzgerald Downgrades DepoMed Inc (DEPO) to Hold
November 8, 2016 7:41 AM ESTCantor Fitzgerald downgraded DepoMed Inc (NASDAQ: DEPO) from Buy to Hold with a price target of $23.00 (from $25.00).
For an analyst ratings summary and ratings history on DepoMed Inc click here. For more ratings news on DepoMed Inc click here.
Shares of DepoMed Inc closed at $22.89 yesterday.
... More